PURMX Enters into Capital Alliance with Nippon Shokubai Co., Ltd. and Initiates Research to Validate the Potential of Fol-Dab8–microRNA Complexes
51 minutes ago
1 min read
PURMX Therapeutics, Inc. (Headquartered in Hiroshima, Japan; President and CEO: Hidetoshi Tahara) is pleased to announce that it has initiated research to validate the potential of complexes comprising microRNA and Fol-Dab8, a drug delivery system (DDS) based on a cationic peptide developed by Nippon Shokubai Co., Ltd. (Headquartered in Osaka, Japan; President & CEO: Kazuhiro Noda; hereinafter “Nippon Shokubai”) that selectively delivers nucleic acids by targeting folate receptorα(FOLR1).
In connection with the commencement of this research, Nippon Shokubai has made an equity investment in PURMX through a private placement of newly issued shares.
Comments